Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Percival

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Blood Neoplasia|June 19, 2025
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasmSuravi Raychaudhuri, Ted A Gooley, Allegra Rasmussen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 23, 2021
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective AnalysisNathan J Moore, Megan Othus, Anna B Halpern, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
JAMA Oncology|May 9, 2024
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation TrialNoam E Kopmar, Kim Quach, Ted A Gooley, et al.
Leukemia & Lymphoma|March 10, 2023
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasmsNoam E Kopmar, Ted Gooley, Niall Curley, et al.
Haematologica|December 16, 2017
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasmRoland B Walter, Megan Othus, Kaysey F Orlowski, et al.
NPJ Biofilms and Microbiomes|May 26, 2025
Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samplesSuravi Raychaudhuri, Hakan Gem, Kevin Chung, et al.
Cancer|December 21, 2021
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemiaKelsey-Leigh A Garcia, Sindhu Cherian, Philip A Stevenson, et al.
Leukemia & Lymphoma|September 14, 2020
Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Nicholas P Howard, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Blood Neoplasia|June 19, 2025
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasmSuravi Raychaudhuri, Ted A Gooley, Allegra Rasmussen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 23, 2021
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective AnalysisNathan J Moore, Megan Othus, Anna B Halpern, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
JAMA Oncology|May 9, 2024
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation TrialNoam E Kopmar, Kim Quach, Ted A Gooley, et al.
Leukemia & Lymphoma|March 10, 2023
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasmsNoam E Kopmar, Ted Gooley, Niall Curley, et al.
Haematologica|December 16, 2017
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasmRoland B Walter, Megan Othus, Kaysey F Orlowski, et al.
NPJ Biofilms and Microbiomes|May 26, 2025
Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samplesSuravi Raychaudhuri, Hakan Gem, Kevin Chung, et al.
Cancer|December 21, 2021
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemiaKelsey-Leigh A Garcia, Sindhu Cherian, Philip A Stevenson, et al.
Leukemia & Lymphoma|September 14, 2020
Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Nicholas P Howard, et al.
Cancers|June 24, 2022
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsColin D Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Pageof 12